<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260607069692N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-28</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Dexamethasone Infusion on Cervical Ripening for Labor Induction</public_title>
      <acronym></acronym>
      <scientific_title>The Efficacy of Extra-amniotic Dexamethasone Infusion in Cervical Ripening for Labor Induction: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93597</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization Method:
This study uses simple randomization. To perform randomization, a list of eligible patients is prepared based on the order of admission to the hospital. Then, for each patient, a number is drawn from a random number table. Based on whether the number is even or odd, the patient is assigned to either the intervention or control group. Even numbers are allocated to the intervention group (extra-amniotic dexamethasone infusion) and odd numbers to the control group (extra-amniotic normal saline infusion). This process continues until the sample size of 60 participants (30 per group) is reached.

Unit of Randomization:
The unit of randomization in this study is individual. Each patient is independently assigned to one of the two study groups.

Stratification:
Stratified randomization is not used in this study.

Randomization Tool:
The randomization tool used in this study is a random number table. This table contains randomly generated numbers with no specific pattern, used for random allocation of patients to the study groups.

Generation of Random Sequence:
To generate the random sequence, a random number table is prepared. Starting from a random point in the table and moving row-wise or column-wise, numbers are drawn sequentially. For each patient, one number is drawn, and based on whether it is even or odd, the patient's group is determined. This sequence continues until the desired sample size (60 participants) is reached. The random sequence is prepared before the start of the study by an individual independent of the principal investigator (e.g., the statistical advisor) to avoid any bias.

Allocation Concealment:
For allocation concealment, the prepared random sequence is placed in sealed, sequentially numbered opaque envelopes. Each envelope contains the allocated group for each patient. The envelopes are opened only at the time of patient enrollment, after obtaining informed consent and confirming eligibility, by an individual not involved in the allocation process. This method prevents selection bias and ensures that the researcher is not aware of the allocated group of each patient in advance.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Gestational Diabetes Melitus. Condition 2: Preeclampsia. Condition 3: Intrahepatic Cholestasis of Pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Extra-amniotic infusion of 20 mg dexamethasone (dexamethasone ampoule 8 mg/2 mL, Iranian manufacturer) combined with normal saline 0.9% via intracervical catheter. The solution is infused once. Six hours after the intervention, labor induction with oxytocin is initiated. Intervention 2: Control group: Extra-amniotic infusion of normal saline (placebo) via intracervical catheter. Normal saline 0.9% is infused once in a volume similar to the intervention group. Six hours after the intervention, labor induction with oxytocin is initiated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Final Report of the Clinical Trial

When:
Upon completion of the report

To whom:
Students, researchers and those who are interested in the matter

Conditions:
For future research and application for labor facilitation and cervix preparation

Where to obtain:
Final report of research or the paper published in Gynecology Journals

How to obtain:
Library of the corresponding university or internet search

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Fatemeh Ghadirikhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mother Blvd</address>
        <city>Bandarabbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1997935816</zip>
        <telephone>+98 916 429 6833</telephone>
        <email>djandaqi@live.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Fatemeh Ghadirikhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mother Blvd.</address>
        <city>Bandarabbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1997935816</zip>
        <telephone>+98 916 429 6833</telephone>
        <email>djandaqi@live.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Term pregnant women at 37 to 42 weeks of gestation.
Bishop score less than 5.
Candidate for termination of pregnancy with obstetric indication.
Requiring labor induction.
Maternal age between 18 and 45 years.
Providing informed consent to participate in the study.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having uterine anomalies.
Having placenta previa.
Having active genital herpes.
Having a history of classical uterine incision.
Having a history of more than one cesarean section.
Having any contraindication to vaginal labor induction.
Not providing informed consent to participate in the study.
Having vasa previa.
Having a history of preterm premature rupture of membranes (PPROM).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O24.4</hc_code>
      <hc_code>O14</hc_code>
      <hc_code>K71.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Gestational diabetes mellitus</hc_keyword>
      <hc_keyword>Pre-eclampsia</hc_keyword>
      <hc_keyword>Toxic liver disease with cholestasis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Extra-amniotic infusion of 20 mg dexamethasone (dexamethasone ampoule 8 mg/2 mL, Iranian manufacturer) combined with normal saline 0.9% via intracervical catheter. The solution is infused once. Six hours after the intervention, labor induction with oxytocin is initiated.</i_keyword>
      <i_keyword>Control group: Extra-amniotic infusion of normal saline (placebo) via intracervical catheter. Normal saline 0.9% is infused once in a volume similar to the intervention group. Six hours after the intervention, labor induction with oxytocin is initiated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bishop score after catheter removal. Timepoint: Immediately after catheter removal (6 hours after intervention). Method of measurement: Vaginal examination and scoring based on the standard Bishop scoring system (range 0-13).</prim_outcome>
      <prim_outcome>Induction-to-delivery time (hours). Timepoint: From initiation of oxytocin infusion to delivery of the newborn. Method of measurement: Recording the time of oxytocin infusion initiation and delivery time using a clock, and calculating the difference in hours.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>First-minute Apgar score. Timepoint: One minute after birth. Method of measurement: Newborn examination and scoring based on the standard Apgar scoring system (range 0-10).</sec_outcome>
      <sec_outcome>Fifth-minute Apgar score. Timepoint: Five minutes after birth. Method of measurement: Newborn examination and scoring based on the standard Apgar scoring system (range 0-10).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bandare-abbas University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-18</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>Mother Blvd.و Bandarabbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
